Phuturdex › Diseases › Male urogenital disease
Drugs in development · updated 30 October 2026
Male urogenital disease: drugs in development
As of 30 October 2026 there are 9 active clinical trials (recruiting or ongoing, phases I–III) on 19 drugs for male urogenital disease. 3 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| ZigakibartBION-1301 | III | 1 | NCT06858319 |
| KTX-2001 | I | 1 | NCT07103018 |
| VIR-5500 | I | 1 | NCT05997615 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| PembrolizumabKEYTRUDA, MK-3475 | III | 2 | NCT07566156 |
| CisplatinCis Platinum, Cisplatine | III | 1 | NCT07566156 |
| Enfortumab VedotinPadcev® | III | 1 | NCT07566156 |
| FinasteridePropecia®, Proscar® | II–III | 1 | NCT07742553 |
| Fluorouracil5-Fluorouracil, Adrucil | III | 1 | NCT07566156 |
| GemcitabineGemcitabin, Gemzar | III | 1 | NCT07566156 |
| Mitomycin CMitomycin, Jelmyto | III | 1 | NCT07566156 |
| Testosterone cypionateAzmiro® | II–III | 1 | NCT07742553 |
| DarolutamideNubeqa, ODM-201 | I–II | 2 | NCT06190899 |
| CarboplatinCarboplatine, Paraplatin | II | 1 | NCT06353906 |
| GedatolisibRevtorpyk® | I–II | 1 | NCT06190899 |
| NivolumabOpdivo, ONO-4538 | II | 1 | NCT06237920 |
| OxybutyninGelnique 3%®, Oxytrol For Women® | II | 1 | NCT04526353 |
| PaclitaxelTaxol, Paxlitaxel | II | 1 | NCT06353906 |
| Relatlimab | II | 1 | NCT06237920 |
Sorted by most advanced phase and number of active trials. Showing 15 of 16 drugs.
All 19 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Prostatic Neoplasms 383 drugs
- Renal cell carcinoma 228 drugs
- Bladder neoplasm 185 drugs
- Chronic renal insufficiency 104 drugs
- Non-small-cell lung carcinoma 726 drugs
- Ovarian neoplasm 411 drugs
- Melanoma 352 drugs
- Metastasis 493 drugs
- Kidney neoplasm 92 drugs
- Transitional cell carcinoma 146 drugs
- Colorectal neoplasm 534 drugs
- IgA glomerulonephritis 48 drugs
Broader categories
- Female urogenital diseases and pregnancy complications 3 drugs
- Female urogenital disease 11 drugs
- Urogenital Diseases 16 drugs
- Genital Diseases 7 drugs
- Genital Neoplasms, Male 6 drugs
- Urologic Diseases 16 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D052801 “Male Urogenital Diseases”.